Search academic texts

Information × Registration Number 0217U000689, 0114U001063 , R & D reports Title To optimize the treatment of patients with "triple negative "metastatic breast cancer popup.stage_title Head Syvak Lyubov Andriyivna, Registration Date 21-02-2017 Organization National Cancer Institute popup.description2 The object of study - 92 hvopyh three negative metastatic breast cancer receiving chemotherapy regimens for CAP and TS.Purpose - to increase the effectiveness of treatment of patients with metastatic three negative breast cancer by applying the most effective chemotherapy regimens based on the definition of clinical and laboratory prognostic factors and individual sensitivity to chemotherapy.Methods and apparatus: clinical, laboratory, instrumental, statistical; Ultrasound machine "Aloca", hematology analyzer BC-3000 biochemistry analyzer "Vitros", spectrophotometer "Thermo", high-speed centrifuge "Biofuge", the thermostat "Termyt."As a result of complex clinical (complaints, physical data), laboratory (hemogram with differential count, erythrocyte sedimentation rate, biochemical parameters of blood, urine), instrumentation (ECG, echo-CG heart radiography UCP, ultrasound ETA or CT UCP, ETA and small pelvis with contrast enhancement) research and analysis of molecular genetic indicators (gene polymorphism GSTP1, MTHFR, protein expression ITSN2) in the standard chemotherapy treatment regimens and SAR TC (4-6 courses) in patients with metastatic breast three negative cancer found that the schemes are moderate (II-III) toxicity, the main manifestations of which were gastrointestinal (91.2 and 87.6%) and hematological (68.4 and 71.2%) toxicity. The dependence of the efficiency of chemotherapeutic treatment (with criteria RECIST) INITIAL level of total proteolytic activity of peripheral blood. Thus, in patients who achieved a complete or partial tumor regression, average total proteolytic activity of peripheral blood was significantly higher (1,05 ± 9,77); p <0.001, if the stabilization process - significantly lower (0,43 ± 0,058); p <0.001, and the progression of the disease - defined its lowest level (0,03 ± 0,05); p <0.001. An impact assessment of infiltration of the tumor stromal lymphoid cells CD3 +, CD4 + and CD8 + on the effectiveness of chemotherapy for metastatic three negative RHZ. Determined that the degree of therapeutic pathomorphosis significantly correlated with proliferative activity marker Ki-67 and the level of infiltration of tumor cells CD8 + (p = 0,02 and p = 0,04 respectively). A longer disease-free period was associated with high levels of CD8 + lymphocytes in the stroma of residual tumor (r = 0,53; p = 0.075) shorter - with high Ki-67 (r = 0,37; p <0.1). Product Description popup.authors А.Аскольський М. Кліманов Н. Касап Н. Майданевич Н.Верьовкіна С. Лялькін popup.nrat_date 2020-04-02 Close